EPIRUS Biopharmaceuticals Executives
EPIRUS Biopharmaceutica employs about 73 people. The company is managed by 5 executives with a total tenure of roughly 171 years, averaging almost 34.0 years of service per executive, having 14.6 employees per reported executive. Discussion of EPIRUS Biopharmaceutica's management performance can provide insight into the enterprise performance.
| Louis Boon Insider Bioassay CLG |
| Jeff Kagy Insider VP Admin |
EPIRUS |
EPIRUS Biopharmaceutica Management Team Effectiveness
The company has return on total asset (ROA) of (0.453) % which means that it has lost $0.453 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.2213) %, meaning that it generated substantial loss on money invested by shareholders. EPIRUS Biopharmaceutica's management efficiency ratios could be used to measure how well EPIRUS Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.EPIRUS Biopharmaceutica Workforce Comparison
EPIRUS Biopharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,457. EPIRUS Biopharmaceutica holds roughly 73.0 in number of employees claiming about 5% of equities under Health Care industry.
EPIRUS Biopharmaceutica Notable Stakeholders
An EPIRUS Biopharmaceutica stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as EPIRUS Biopharmaceutica often face trade-offs trying to please all of them. EPIRUS Biopharmaceutica's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting EPIRUS Biopharmaceutica's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Louis Boon | Bioassay CLG | Profile | |
| Jeff Kagy | VP Admin | Profile | |
| Bram Bout | Head BV | Profile | |
| Emile Corven | Head PD | Profile | |
| Jason Yap | Head Director | Profile |
EPIRUS Biopharmaceutica Workforce Analysis
Traditionally, organizations such as EPIRUS Biopharmaceutica use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare EPIRUS Biopharmaceutica within its industry.EPIRUS Biopharmaceutica Manpower Efficiency
Return on EPIRUS Biopharmaceutica Manpower
| Revenue Per Employee | 9.6K | |
| Revenue Per Executive | 140.2K | |
| Net Loss Per Employee | 714.9K | |
| Net Loss Per Executive | 10.4M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in EPIRUS Pink Sheet
If you are still planning to invest in EPIRUS Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EPIRUS Biopharmaceutica's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |